Drug Trial Radar · NCT07903194
A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Oct 27, 2026
Primary completion
Dec 21, 2027
Study completion Aug 29, 2028
Sponsor
- Lead sponsor
- Shanghai Mabgeek Biotech.Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). A total of 210 patients aged 18 to 75 years with bilateral CRSwNP are planned to be enrolled and randomized in a 1:1 ratio to receive either MG-K10 or placebo. During the first 24 weeks, participants will receive MG-K10 or placebo; they will subsequently enter a 28-week maintenance treatment period, during which the original placebo group will switch to receive MG-K10, and blinding will be maintained in both groups. MG-K10 is administered subcutaneously once every 4 weeks. Both groups will receive mometasone furoate nasal spray as background therapy from the run-in period through the end of the study. Following the treatment period, participants will be followed up for 8 weeks up to Week 60. The co-primary endpoints are the changes from baseline in Nasal Polyp Score (NPS) and Nasal Congestion Score (NCS) at Week 24; other symptoms, quality of life, safety, pharmacokinetics, pharmacodynamics, and immunogenicity will also be evaluated.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
MG-K10Biological
MG-K10 humanized monoclonal antibody injection administered via subcutaneous injection. During the first 24 weeks, the MG-K10 group receives an initial dose of 600 mg, followed by 300 mg every 4 weeks, for a total of 6 doses. At Week 24, the MG-K10 group receives 300 mg plus matching placebo, while the original placebo group receives an initial dose of 600 mg; thereafter, both groups receive 300 mg every 4 weeks, for a total of 7 doses during the maintenance treatment period.
PlaceboDrug
Placebo matching MG-K10 administered via subcutaneous injection. During the first 24 weeks, the placebo group receives an initial dose of 4.0 mL, followed by 2.0 mL every 4 weeks, for a total of 6 doses. At Week 24, the MG-K10 group concurrently receives matching placebo 2.0 mL to maintain blinding.
Mometasone Furoate Nasal SprayDrug
Mometasone furoate nasal spray administered as background therapy for all participants at 200 μg daily from the run-in period through study completion at Week 60: 2 actuations per nostril once daily, 50 μg per actuation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Bilateral Nasal Polyp Score (NPS)Time frame: Baseline and Week 24
- Change From Baseline in Nasal Congestion Score (NCS)Time frame: Baseline and Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.